Long acting GLP-1 receptor agonist (injectable)
Semaglutide injection
SEMA_SC
Doses in this pooled treatment
- Semaglutide 1.0 mg subcutaneous once weekly
- Semaglutide maximum tolerated dose injection once weekly
- Semaglutide 2.4 mg subcutaneous once weekly
- Semaglutide 0.5 mg subcutaneous once weekly
- Semaglutide 0.5 mg injection
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.4 mg injection once daily
- Semaglutide 0.1 mg injection once daily
- Semaglutide 0.2 mg injection once daily
- Semaglutide 0.25 mg injection
- Semaglutide 2.0 mg subcutaneous once weekly
- Semaglutide 1.5 mg injection once weekly
- Semaglutide 8 mg injection once weekly
- Semaglutide 16 mg injection once weekly
- Semaglutide 0.1072 mg injection
- Semaglutide 1.7 mg injection once weekly
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.05 mg injection once daily
- Semaglutide 0.3 mg injection once daily
- Semaglutide flexible dose injection once weekly
- Semaglutide 2.4 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.32 (-1.71 to -0.90) | 0.87 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.57 (-1.84 to -1.31) | 0.96 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.72 (-1.42 to 0.07) | 0.76 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.78 (-2.84 to -0.57) | 0.81 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.77 (-1.41 to -0.09) | 0.58 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.47 (-2.39 to -0.47) | 0.80 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.26 (-2.09 to -0.28) | 0.88 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.55 (-2.15 to -0.84) | 0.89 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -0.48 (-1.46 to 0.58) | 0.81 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.71 (-2.67 to -0.59) | 0.97 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.85 (-5.19 to -2.49) | 0.90 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -4.89 (-8.02 to -1.27) | 0.88 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -4.31 (-5.60 to -3.09) | 0.91 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -5.49 (-8.74 to -1.92) | 0.96 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -10.13 (-14.67 to -4.69) | 0.96 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.24 (-7.67 to 2.08) | 0.72 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.35 (-7.80 to 1.83) | 0.78 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.60 (-8.27 to 1.16) | 0.81 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -10.16 (-14.43 to -4.16) | 0.98 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.26 (-7.10 to 2.93) | 0.76 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 14.58 (4.66 to 37.39) | 0.80 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 16.78 (8.14 to 32.12) | 0.95 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 7.02 (1.03 to 33.33) | 0.47 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.17 (0.04 to 0.56) | 0.60 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.42 (0.73 to 7.47) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.12 (0.50 to 2.19) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.77 (0.37 to 1.54) | 0.60 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -3.26 (-4.85 to -1.62) | 0.74 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -1.10 (-5.41 to 4.37) | 0.68 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.23 (-7.20 to 0.76) | 0.69 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -2.48 (-12.19 to 7.67) | 0.56 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -6.75 (-10.49 to -3.01) | 0.86 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Placebo | MD -1.88 (-13.38 to 10.03) | 0.60 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -4.37 (-9.80 to 1.51) | 0.83 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.20 (-9.10 to -0.61) | 0.90 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 8.33 (1.50 to 26.73) | 0.91 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 10.93 (3.32 to 29.03) | 0.88 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 8.38 (1.92 to 38.04) | 0.68 |
| Type 2 diabetes (adults) | Three point MACE | longest follow-up | Placebo | HR 0.74 (0.42 to 1.35) | 0.70 |
| Type 2 diabetes (adults) | Hospitalization for heart failure | longest follow-up | Placebo | HR 1.11 (0.59 to 2.30) | 0.31 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.17 (-0.01 to 2.29) | 0.91 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.12 (-0.93 to 3.40) | 0.75 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.92 (0.79 to 1.07) | 0.56 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.31 (1.64 to 3.42) | 0.30 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.64 (2.80 to 4.74) | 0.28 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.34 (2.38 to 4.71) | 0.33 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.13 (1.73 to 2.65) | 0.29 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.40 (1.83 to 3.29) | 0.27 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 3.63 (2.08 to 6.69) | 0.28 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 4.17 (0.84 to 27.29) | 0.12 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.44 (0.10 to 1.83) | 0.55 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 1.96 (0.92 to 5.14) | 0.24 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.29 (0.02 to 3.06) | 0.74 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 1.46 (0.30 to 6.79) | 0.47 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -5.84 (-7.76 to -4.21) | 0.82 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -2.77 (-10.56 to 3.56) | 0.45 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -1.43 (-11.03 to 7.86) | 0.57 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -13.97 (-19.48 to -6.92) | 0.57 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -11.27 (-13.37 to -9.32) | 0.70 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -12.08 (-14.53 to -9.15) | 0.64 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -12.71 (-16.87 to -7.39) | 1.00 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -8.66 (-14.55 to -2.75) | 0.67 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 8.07 (2.80 to 18.51) | 0.73 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 17.23 (9.65 to 26.47) | 0.58 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 8.99 (1.98 to 30.94) | 0.99 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 104 to 182 (target week 104) | Placebo | OR 6.15 (1.92 to 18.22) | 0.99 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 14.16 (8.43 to 24.98) | 0.69 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 15.67 (3.76 to 38.76) | 0.85 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 104 to 182 (target week 104) | Placebo | OR 9.90 (2.54 to 29.53) | 0.85 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 12.25 (8.06 to 19.67) | 0.62 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 18.79 (5.12 to 44.66) | 0.90 |
| Overweight or obesity without diabetes (adults) | Weight loss of 20 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 15.74 (9.52 to 27.58) | 0.61 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 2.17 (-6.04 to 10.09) | 0.72 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.85 (-0.32 to 2.47) | 0.55 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.20 (0.89 to 1.61) | 0.54 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.90 (1.01 to 3.29) | 0.57 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.59 (3.10 to 4.28) | 0.50 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.09 (3.84 to 6.87) | 0.48 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.21 (1.79 to 2.79) | 0.43 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.91 (2.31 to 3.85) | 0.33 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 5.29 (2.10 to 14.12) | 0.27 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 2.38 (1.09 to 5.39) | 0.36 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Nausea | longest follow-up | Placebo | HR 0.69 (0.01 to 56.69) | 0.67 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Vomiting | longest follow-up | Placebo | HR 1.59 (0.10 to 18.17) | 0.49 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Diarrhea | longest follow-up | Placebo | HR 14.76 (0.90 to 376) | 0.03 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Constipation | longest follow-up | Placebo | HR 2.53 (0.12 to 36.02) | 0.41 |
| Children and adolescents with obesity | BMI standard deviation score change | weeks 40 to 104 (target week 68) | Placebo | MD -0.96 (-1.27 to -0.54) | 0.99 |
| Children and adolescents with obesity | Serious adverse events | longest follow-up | Placebo | HR 1.27 (0.31 to 5.54) | 0.44 |
| Children and adolescents with obesity | Nausea | longest follow-up | Placebo | HR 2.66 (0.82 to 8.46) | 0.37 |
| Children and adolescents with obesity | Vomiting | longest follow-up | Placebo | HR 3.82 (0.97 to 13.29) | 0.55 |
| Children and adolescents with obesity | Diarrhea | longest follow-up | Placebo | HR 1.15 (0.35 to 3.99) | 0.62 |
| Children and adolescents with obesity | Constipation | longest follow-up | Placebo | HR 3.27 (0.49 to 33.36) | 0.28 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.30 (-1.11 to 0.52) | 0.60 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD -1.13 (-2.07 to -0.21) | 0.98 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 2.96 (0.12 to 96.74) | 0.27 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 1.42 (0.34 to 6.09) | 0.42 |
| Chronic kidney disease with diabetes | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.91 (0.76 to 36.73) | 0.29 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 0.76 (0.12 to 4.49) | 0.81 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Serious adverse events | longest follow-up | Placebo | HR 1.57 (0.69 to 3.62) | 0.21 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.62 (0.55 to 73.12) | 0.18 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Nausea | longest follow-up | Placebo | HR 3.53 (1.74 to 7.37) | 0.42 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Vomiting | longest follow-up | Placebo | HR 11.94 (3.48 to 57.29) | 0.15 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Diarrhea | longest follow-up | Placebo | HR 1.80 (0.89 to 3.69) | 0.42 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Constipation | longest follow-up | Placebo | HR 1.82 (0.78 to 4.41) | 0.54 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 7.09 (0.98 to 122) | 0.18 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Resolution of steatohepatitis without worsening of fibrosis | weeks 48 to 104 (target week 72) | Placebo | OR 2.99 (0.99 to 7.97) | 0.97 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Fibrosis improvement without worsening of steatohepatitis | weeks 48 to 104 (target week 72) | Placebo | OR 0.85 (0.22 to 2.60) | 0.38 |
| Polycystic ovary syndrome | Regular menstrual cycles | weeks 12 to 52 (target week 26) | Standard care or no added treatment | OR 3.27 (0.72 to 14.84) | 0.79 |
| Alcohol use disorder | Serious adverse events | longest follow-up | Placebo | HR 0.56 (0.01 to 41.81) | 0.63 |
| Alcohol use disorder | Nausea | longest follow-up | Placebo | HR 6.01 (1.07 to 26.38) | 0.10 |
| Alcohol use disorder | Vomiting | longest follow-up | Placebo | HR 0.66 (0.08 to 4.86) | 0.78 |
Trials
- S00342679 randomized · 24 weeks
- S00303250 randomized · 34.76 weeks
- S00300231 randomized · 36 weeks
- S0034372025 · 180 randomized · 24 weeks
- NCT06896981Comparison Between the Effects of Low-Dose Semaglutide With Metformin vs. Metformin Alone Over Metabolic Profile in Obese Polycystic Ovary Syndrome: A Phase II Randomized Controlled Trial2025 · 31 randomized · 16 weeks
- ADJUST-T1DEfficacy and Safety of Once Weekly Semaglutide in Adults With Obesity and Inadequately Controlled Type 1 Diabetes Using Hybrid Closed-Loop System.2023 · 72 randomized · 26 weeks
- S0029912023 · 220 randomized · 13.04 weeks
- NCT06974825A Randomized, Double-blind, Placebo and Positive Drug Parallel-controlled Phase IIa Clinical Study Protocol to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple-dose BGM0504 Injection in Patients With Type 2 Diabetes Mellitus2023 · 67 randomized · 18 weeks
- SURMOUNT-5A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities2023 · 751 randomized · 72 weeks
- S0034222023 · 64 randomized · 12 weeks
- NCT05786521The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance2023 · 20 randomized · 20 weeks
- NCT05520775Human Laboratory Screening of Semaglutide for Alcohol Use Disorder2022 · 48 randomized · 9 weeks
- COMBINE 2A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Semaglutide, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With a GLP 1 Receptor Agonist. COMBINE 22022 · 683 randomized · 52 weeks
- BARI-STEPBARI-STEP:A Double-blinded, Randomised, Placebo-controlled Trial of Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery.2022 · 70 randomized · 68 weeks
- NCT05616013A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women2022 · 507 randomized · 48 weeks
- NCT05530577Effects of Semaglutide on Nicotine Intake and Smoking Lapse2022 · 24 randomized · 9 weeks
- NCT05514535Efficacy and Safety of Once-weekly Semaglutide S.C. 2.0 mg as Add-on to Dose-reduced Insulin Glargine vs Titrated Insulin Glargine in Participants With Type 2 Diabetes and Overweight2022 · 573 randomized · 40 weeks
- STABLE Wt LossShort- and Long-term Effects of Once Weekly Semaglutide 2.4 mg on Appetite, Eating Behavior, and Psychosocial Status2022 · 120 randomized · 60 weeks
- HISTORIHome-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes2022 · 154 randomized · 30 weeks
- NCT05486065Investigation of Once-weekly Semaglutide S.C. Dose-Response in Patients With Type 2 Diabetes and Overweight - a Participant- and Investigator-blinded and Sponsor Open-label Study2022 · 245 randomized · 40 weeks
- STEP 10Efficacy and Safety of Subcutaneous Semaglutide 2.4 mg Once-weekly in Subjects With Obesity and Prediabetes2021 · 207 randomized · 52 weeks
- REMODELRenal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease2021 · 106 randomized · 52 weeks
- ENDISImpact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM Patients2021 · 91 randomized · 12 weeks
- STEP HFpEF DMEffect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes2021 · 616 randomized · 52 weeks
- TRANSITION-T2DTransition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D) A Prospective Randomized Controlled Trial2021 · 60 randomized · 26 weeks
- STRIDEEffects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease2020 · 792 randomized · 52 weeks
- S0029462020 · 32 randomized · 26 weeks
- STEP7Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity.2020 · 375 randomized · 44 weeks
- NCT04451837Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology2020 · 239 randomized · 26.07 weeks
- SEMATThe Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity2020 · 25 randomized · 24 weeks
- S0034322020 · 218 randomized · 52 weeks
- SUSTAIN FORTEEfficacy and Safety of Semaglutide 2.0 mg s.c. Once-weekly Compared to Semaglutide 1.0 mg s.c. Once-weekly in Subjects With Type 2 Diabetes2019 · 961 randomized · 40 weeks
- NCT03842202Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity2019 · 72 randomized · 20 weeks
- S0034272019 · 148 randomized · 52.14 weeks
- NCT04102189Effect and Safety of Semaglutide 2.4 mg Once Weekly on Weight Management in Adolescents With Overweight or Obesity2019 · 201 randomized · 68 weeks
- STEP 8Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity2019 · 338 randomized · 68 weeks
- NCT03987451Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis2019 · 71 randomized · 48 weeks
- STEP 6Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity2019 · 401 randomized · 68 weeks
- NCT03951753The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus2019 · 117 randomized · 28 weeks
- STEP 1Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity2018 · 1,961 randomized · 68 weeks
- NCT03596450Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial2018 · 1,278 randomized · 104.36 weeks
- STEP 3Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity2018 · 611 randomized · 68 weeks
- STEP 5Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity2018 · 304 randomized · 104 weeks
- SUSTAIN 11Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes2018 · 1,748 randomized · 52 weeks
- NCT03357380A Trial Investigating the Effect of Subcutaneous Semaglutide on Liver Fibrosis Assessed by Magnetic Resonance Elastography in Subjects With Non-alcoholic Fatty Liver Disease2017 · 67 randomized · 72 weeks
- SUSTAIN 9Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus. A 30-week Randomised, Double-blind, Placebo-controlled Trial2017 · 302 randomized · 30 weeks
- SUSTAIN 10Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes2017 · 577 randomized · 30 weeks
- SUSTAIN 8Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes2017 · 788 randomized · 52 weeks
- SUSTAINEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial2017 · 868 randomized · 30 weeks
- NCT02970942This Trial is Conducted Globally. The Aim of This Trial is to Investigate Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis2016 · 320 randomized · 72 weeks
- SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes2016 · 1,201 randomized · 40 weeks
- NCT02453711Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus2015 · 957 randomized · 52 weeks
- NCT02212067A Single-centre, Randomised, Double-blind, Multiple-dose, Placebo-controlled, Parallel-group Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes2014 · 75 randomized · 12 weeks
- SUSTAIN™ 5Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes2014 · 397 randomized · 30 weeks
- SUSTAIN™Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes2014 · 308 randomized · 30 weeks
- SUSTAIN™1Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes2014 · 388 randomized · 30 weeks
- SUSTAIN™ 4Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes2014 · 1,089 randomized · 30 weeks
- SUSTAIN™Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy2014 · 601 randomized · 56 weeks
- SUSTAIN™ 6A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)2013 · 3,297 randomized · 104 weeks
- SUSTAIN™ 3Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)2013 · 813 randomized · 56 weeks
- SUSTAIN™ 2Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)2013 · 1,231 randomized · 56 weeks